Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock
Source: View publication →
In a multicenter randomized trial of patients with septic shock, the addition of low-dose vasopressin to norepinephrine did not significantly reduce 28-day mortality compared to norepinephrine alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The VASST trial established that low-dose vasopressin does not provide an overall survival advantage when used as a primary adjunct in established septic shock compared to norepinephrine. However, it confirmed the safety and catecholamine-sparing effect of vasopressin. Today, vasopressin is widely utilized as a second-line adjunctive vasopressor to reduce high catecholamine requirements rather than to directly improve mortality.
Historical Context
Prior to VASST, it was widely recognized that established septic shock is characterized by a relative deficiency of endogenous vasopressin. Smaller preliminary studies had suggested that exogenous vasopressin administration could robustly restore mean arterial pressure and reduce the need for high-dose catecholamines, which were known to carry risks of ischemia and arrhythmias. The VASST trial was a highly anticipated, landmark study designed to test whether this potent physiologic and catecholamine-sparing effect would translate into a tangible survival benefit. Its neutral primary outcome profoundly shaped subsequent Surviving Sepsis Campaign guidelines, solidifying vasopressin's role as a secondary adjunctive agent rather than a first-line alternative.
Guided Discussion
High-yield insights from every perspective
Based on the pathophysiology of septic shock, what is the rationale for adding vasopressin, a non-adrenergic vasopressor, to a patient already receiving norepinephrine?
Key Response
Septic shock is characterized by profound vasodilation and relative vasopressin deficiency. Vasopressin acts on V1 receptors on vascular smooth muscle to cause vasoconstriction independent of alpha-1 adrenergic receptors, sparing the heart from excessive chronotropic and inotropic effects associated with escalating catecholamine doses.
In managing a patient with septic shock whose mean arterial pressure remains below 65 mm Hg despite adequate fluid resuscitation and a norepinephrine infusion, at what dose threshold of norepinephrine should you typically consider adding vasopressin according to the VASST trials practical implications?
Key Response
While VASST showed no overall mortality difference, it highlighted the safety of adding low-dose vasopressin (up to 0.03 U/min). Clinically, this translates to adding vasopressin early-to-mid course, often when norepinephrine requirements reach escalating levels (e.g., 0.25 to 0.5 mcg/kg/min), to achieve catecholamine-sparing effects and prevent refractory shock.
The VASST trial identified a potential mortality benefit in the less severe septic shock stratum (baseline norepinephrine less than 15 mcg/min). How does this subgroup finding influence your hemodynamic management strategy, and what are the physiologic risks of starting vasopressin too late in refractory shock?
Key Response
The subgroup analysis suggested that starting vasopressin before catecholamine requirements become extreme might be beneficial by mitigating prolonged adrenergic toxicity. Starting it too late in severe shock might be futile due to established irreversible microvascular dysfunction, profound acidosis blunting receptor responsiveness, and the risk of ischemic complications in profoundly compromised vascular beds.
Given that VASST demonstrated no overall mortality benefit but confirmed a catecholamine-sparing effect, how do you weigh the cost and potential adverse effects of vasopressin against the known toxicities of high-dose norepinephrine when individualizing a dual-vasopressor strategy?
Key Response
The key teaching point is individualized therapy. Physicians must recognize when a patient is experiencing catecholamine toxicity, such as severe tachyarrhythmias, and use vasopressin as a sparing agent. This decision balances mitigating adrenergic toxicity against the risk of vasopressin-induced profound vasoconstriction in vulnerable splanchnic or digital beds, requiring careful bedside assessment of perfusion.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The VASST trial utilized an unadjusted subgroup analysis based on baseline norepinephrine dose severity, which yielded a nominally significant P-value for the less severe shock stratum. What are the statistical limitations of this a priori subgroup analysis, and how should a future trial be designed to definitively test this hypothesis?
Key Response
Subgroup analyses, even when predefined, are prone to Type I errors due to multiple testing and reduced power. Furthermore, the VASST test for interaction between treatment and severity stratum was not statistically significant (P=0.10). A definitive trial must be prospectively powered for this specific early vs late population as the primary endpoint.
As a reviewer evaluating the VASST trial, how does the allowance of open-label vasopressors by treating physicians introduce a potential co-intervention bias that could mask a true treatment effect of vasopressin?
Key Response
In a trial titrating blinded study drug against open-label norepinephrine to a MAP target, physicians unblinded to the overall clinical trajectory might rapidly escalate open-label catecholamines based on bedside bias. This could blur the physiologic separation between groups, minimizing the detectable difference in 28-day mortality and threatening the trials internal validity.
How does the VASST trial inform the Surviving Sepsis Campaign guidelines regarding the strength of recommendation for adding vasopressin, and does the evidence justify its use as a first-line agent or purely as an adjunct?
Key Response
The Surviving Sepsis Campaign guidelines recommend adding vasopressin (up to 0.03 U/min) to norepinephrine with the intent of raising MAP to target or decreasing norepinephrine dosage (Weak recommendation, moderate-quality evidence). Because VASST showed no mortality superiority over norepinephrine alone but established its safety as a catecholamine-sparing agent, guidelines firmly position it as a second-line adjunct.
Clinical Landscape
Noteworthy Related Trials
SOAP II Trial
Tested
Dopamine
Population
Patients with shock requiring vasopressors
Comparator
Norepinephrine
Endpoint
28-day mortality
SEPSISPAM Trial
Tested
High MAP target (80 to 85 mm Hg)
Population
Patients with septic shock requiring vasopressors
Comparator
Low MAP target (65 to 70 mm Hg)
Endpoint
28-day mortality
VANISH Trial
Tested
Early vasopressin infusion
Population
Patients with septic shock
Comparator
Norepinephrine infusion
Endpoint
Kidney failure-free days at 28 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis